

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

Alexa Fluor® 647 Rabbit Anti-Active Caspase-3

RRID:AB_1727414

Type: Antibody

Proper Citation

BD Biosciences Cat# 560626, RRID:AB_1727414

Antibody Information

URL: http://antibodyregistry.org/AB_1727414

Proper Citation: BD Biosciences Cat# 560626, RRID:AB_1727414

Target Antigen: Caspase-3 Active Form

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Alexa Fluor® 647 Rabbit Anti-Active Caspase-3

Description: This monoclonal targets Caspase-3 Active Form

Target Organism: human

Clone ID: Clone C92-605

Antibody ID: AB_1727414

Vendor: BD Biosciences

Catalog Number: 560626

Record Creation Time: 20231110T073011+0000

Record Last Update: 20260829T074835+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor® 647 Rabbit Anti-Active Caspase-3.

No alerts have been found for Alexa Fluor® 647 Rabbit Anti-Active Caspase-3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Menezes-Silva L, et al. (2026) Hormonal rewiring of immunity during dietary restriction ensures host defense and systemic glucose conservation. *Immunity*, 59(3), 700.

Soliman N, et al. (2025) Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors. *Cancer research*, 85(14), 2679.

Stok JE, et al. (2025) Vault RNAs aid RNA virus infection by facilitating cytoplasmic localization of hnRNP C and ELAVL1. *Cell reports*, 44(6), 115823.

Kim Y, et al. (2025) IL-21 shapes the B cell response in a context-dependent manner. *Cell reports*, 44(1), 115190.

Stinson JA, et al. (2025) Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control. *Molecular cancer therapeutics*, 24(1), 118.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. *Cell reports*, 43(5), 114141.

Jain J, et al. (2024) Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice. *iScience*, 27(12), 111470.

Barra JM, et al. (2024) Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells. *Cell reports*, 43(11), 114994.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.

Afsahi A, et al. (2023) LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling. *Frontiers in immunology*, 14, 1179827.

Zhong W, et al. (2023) Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors. *Cancer research*, 83(16), 2790.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. *Cell reports. Medicine*, 3(9), 100744.

Leung W, et al. (2022) SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. *Cancer discovery*, 12(7), 1782.

Huang H, et al. (2021) In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8⁺ T cell fate decisions. *Cell*, 184(5), 1245.

Stutz MD, et al. (2021) Macrophage and neutrophil death programs differentially confer resistance to tuberculosis. *Immunity*, 54(8), 1758.

Gong C, et al. (2021) Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. *Molecular cell*, 81(19), 4059.

Matsuda K, et al. (2021) A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro. *Cell reports methods*, 1(8), 100122.

Kumagai S, et al. (2020) An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. *Immunity*, 53(1), 187.

Béguelin W, et al. (2020) Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. *Cancer cell*, 37(5), 655.

Lee S, et al. (2019) A Secreted Viral Nonstructural Protein Determines Intestinal Norovirus Pathogenesis. *Cell host & microbe*, 25(6), 845.